| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $122,078,124 ) (Continued on the next page) |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI189789 | Molecular mechanism of tetanus neurotoxin pathogenesis | 000 | 2 | NIH | 4/1/2026 | $833,213 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI139087 | Structure and Function of C. Difficile Toxins | 000 | 6 | NIH | 4/1/2026 | $3,307,473 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01DK135707 | Isoform- and Sex-Specific Functions of CGRP in Gastrointestinal Motility | 000 | 4 | NIH | 4/13/2026 | $660,177 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AI177778 | Elucidating the functional mechanism of NLRP3 inflammasome activation | 000 | 4 | NIH | 4/24/2026 | $708,000 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01CA287076 | Activating gasdermin pores to induce pyroptosis and stimulate anti-tumor immunity | 000 | 3 | NIH | 4/1/2026 | $733,069 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD112379 | Metabolic control of the neural crest epigenome | 001 | 3 | NIH | 4/2/2026 | $56,054 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HD114338 | Developing novel MR tools to optimize surgical planning and fetal outcome in TTTS | 001 | 3 | NIH | 4/13/2026 | $723,857 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K08HL173561 | Endothelial cell-based therapy for pulmonary vascular disease using induced pluripotent stem cells | 000 | 3 | NIH | 3/24/2026 | $167,940 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL146128 | MSC Exosome Treatment for BPD: Impact on Immunity and Lung Development | 000 | 8 | NIH | 3/23/2026 | $867,215 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL158192 | High resolution lineage tracing of developmental hematopoiesis | 001 | 4 | NIH | 3/24/2026 | $22,059 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS124212 | Motion Compensated fMRI for Pre-Surgical Planning in Epilepsy | 000 | 4 | NIH | 4/10/2026 | $665,210 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS134948 | Paradoxical Sensory Responses: A Clue Towards Understanding Biotypes in Autism Spectrum Disorder and Other Neurodevelopmental Disorders | 000 | 3 | NIH | 3/24/2026 | $461,954 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL178815 | Intravenous oxygen for the treatment of cardiac arrest | 000 | 2 | NIH | 3/24/2026 | $859,295 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K08AR080992 | Development of resident memory T cells in the synovium | 000 | 5 | NIH | 3/23/2026 | $173,340 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL163513 | High-throughput Phenotyping of iPSC-derived Airway Epithelium by Multiscale Machine Learning Microscopy | 001 | 4 | NIH | 3/25/2026 | $23,409 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | T32HD098061 | Neonatal Research Training Program | 000 | 8 | NIH | 4/10/2026 | $499,031 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | T32HD040128 | Research Training in Pediatric Emergency Medicine | 002 | 23 | NIH | 4/10/2026 | $292,448 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL162642 | Balancing epithelial cell resistance and resilience to respiratory viral infections | 000 | 4 | NIH | 4/21/2026 | $814,724 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R35GM145368 | Discovery of novel regulatory territories in the TNF/LT locus | 000 | 5 | NIH | 4/27/2026 | $442,500 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01MH130356 | Effects of 16p11.2 copy number variation on neuronal development and pathology | 000 | 4 | NIH | 3/24/2026 | $813,612 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R35HL150876 | Cell-cell interactions governing lung epithelial progenitor cells | 001 | 7 | NIH | 3/25/2026 | $26,550 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL161507 | A Novel computational approach to optimize Fontan and improve surgical predictability | 001 | 5 | NIH | 4/21/2026 | $17,945 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL155632 | Transcription Factor 4 Maintain Endothelial identity to Oppose Heart Failure | 001 | 5 | NIH | 4/20/2026 | $15,050 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AR083424 | T peripheral regulatory cells as modulators of T cell-B cell interactions in arthritis | 001 | 3 | NIH | 5/4/2026 | $25,765 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | UH3NS132138 | Development of an Efficient High Throughput Technique for the Identification of High-Impact Non-Coding Somatic Variants Across Multiple Tissue Types | 000 | 4 | NIH | 3/30/2026 | $674,029 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AR080079 | Epigenetic dysregulation of muscle differentiation in Kabuki syndrome | 001 | 5 | NIH | 5/4/2026 | $26,501 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U01AI191210 | Robust verification of genetic variant-associated candidate off-target sites | 000 | 2 | NIH | 4/27/2026 | $1,675,364 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R34EY038248 | PEDIATRIC INHERITED RETINAL DISORDERS: TARGETING CRYPTIC SPLICING DEFECTS | 000 | 1 | NIH | 4/28/2026 | $534,000 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL152133 | Enhancing endothelial cell engraftment via transplantation of exogenous mitochondria | 000 | 5 | NIH | 5/4/2026 | $844,303 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R00HL184327 | Organ specific effects of platelet transfusions in neonates | 000 | 1 | NIH | 5/4/2026 | $443,978 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL163937 | CMYA5 regulation of cardiac dyad structure and function | 000 | 4 | NIH | 4/27/2026 | $590,138 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS138140 | Molecular and Circuit Mechanisms of Memory Prevention and Removal | 000 | 3 | NIH | 4/21/2026 | $515,735 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K23MH138261 | Academic Detailing to Optimize PrEP Implementation in Pediatric Primary Care Settings: ADOPT-PrEP | 000 | 2 | NIH | 4/17/2026 | $193,754 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01DK048106 | GLYCOSPHINGOLIPIDS AS SENSORS FOR EPITHELIAL CELL-AUTONOMOUS HOST DEFENSE AT MUCOSAL SURFACES MEDIATED BY DOWN-REGULATION OF THE APICAL ENDOSOME | 000 | 32 | NIH | 3/18/2026 | $901,234 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K99EY037821 | Targeting SARM1 as a Therapeutic Strategy for Autosomal Dominant Optic Atrophy (ADOA) and Leber Hereditary Optic Neuropathy (LHON) | 000 | 1 | NIH | 4/17/2026 | $132,837 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01HL171405 | Pericyte contribution to capillary remodeling in pulmonary arterial hypertension | 001 | 3 | NIH | 4/17/2026 | $23,842 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K08DK142004 | Mechanisms of hypothalamic-pituitary-adrenal axis suppression and recovery after long-term glucocorticoids | 000 | 1 | NIH | 4/17/2026 | $168,543 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R37NS035129 | Human Epilepsy Genetics - Mosaic Mutations in Focal Epilepsy | 001 | 27 | NIH | 3/18/2026 | $85,509 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R21CA296527 | Advanced Genetic Engineering to Unravel Tumor-Specific B Cell Responses | 001 | 2 | NIH | 4/16/2026 | $20,803 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R21AI199018 | Molecular Mechanisms of Aire in Transcriptional Regulation | 000 | 1 | NIH | 4/17/2026 | $267,000 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01NS124879 | Developmentally Programmed Remodeling of Apical ECM | 001 | 5 | NIH | 3/18/2026 | $43,723 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | T32HL007572 | Research Methods in Pediatric Cardiovascular Disease | 000 | 42 | NIH | 5/8/2026 | $783,504 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U01AA030185 | Cardiovascular disease in fetal alcohol spectrum disorder | 001 | 5 | NIH | 5/12/2026 | $343,380 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R21OD037909 | A modular system for murine CRISPR genome and epigenome editing | 001 | 2 | NIH | 5/8/2026 | $64,080 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01DK125898 | Insulin Regulation of Hepatic Function via Zone-Specific Transcriptional Programs | 000 | 5 | NIH | 4/8/2026 | $497,671 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | K01HL171354 | Associations between Perfluoroalkyl Substances (PFAS) Exposure and Aeroallergen Sensitization among Infants at High-Risk for Developing Asthma | 000 | 3 | NIH | 5/7/2026 | $161,442 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U24NS137481 | Brain Malformation Expert Panels for Gene and Variant Curation | 002 | 3 | NIH | 4/23/2026 | $0 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | U24NS137481 | Brain Malformation Expert Panels for Gene and Variant Curation | 002 | 3 | NIH | 4/23/2026 | $0 |
| | 2026 | 2026 | CHILDREN'S HOSPITAL CORPORATION, THE | 300 LONGWOOD AVE | BOSTON | MA | 02115-5724 | SUFFOLK | USA | R01AG078423 | Shared Genetic and Environmental Influences on Age-Related Hearing Loss, Cognitive Decline, and Dementia Risk | 000 | 4 | NIH | 4/28/2026 | $716,945 |
|
